Abstract. High-fat diets (HFDs) are a risk factor for colorectal cancer. The present study investigated whether HFDs increase colon cancer metastasis in BALB/c mice. A total of 40 BALB/c mice were divided into four groups, including the tumor, tumor-HFD, HFD and control groups. After 3 weeks, the tumor weights and metastases were observed. The serum levels of triglyceride, total cholesterol, lapin, interleukin-6 (IL-6) and tumor necrosis factor were analyzed using ELISA. The CD34, vascular endothelial growth factor (VEGF) and angiotensin 2 (ANG2) protein and mRNA levels in tumor tissues were analyzed with immunohistochemistry and reverse transcription-polymerase chain reaction. The metastasis frequency increased in the tumor-HFD group. However, there was no difference in the mean tumor weight between the tumor-HFD and tumor groups. The serum cholesterol levels were increased in the tumor-HFD and HFD groups compared with the control group. The levels of serum IL-6 and tumor necrosis factor-α were increased in the tumor-HFD group compared with other groups. The CD34 protein level, and VEGF protein and mRNA levels were increased in the tumor-HFD group compared with the tumor group. No difference was identified between the ANG2 protein and mRNA levels in of the two groups. It was concluded that HFD increased the serum level of cholesterol and cytokines, and potentially induced tumor angiogenesis, promoting transplanted orthotopic colon tumor metastasis in BALB/c mice.
Introduction
Colorectal cancer (CRC) is the second-leading cause of cancer-associated mortality worldwide (1) . Patients are frequently initially diagnosed at an advanced stage of disease, when distant metastasis is likely to be present. The mechanisms of metastasis in CRC remain incompletely characterized.
High-fat diets (HFDs) are a risk factor for numerous conditions, including obesity (2), insulin resistance (3, 4) , non-alcoholic fatty liver disease (5), hypertension and atherosclerosis (6) . HFD, particularly when including animal fat, is also a risk factor for CRC (7) (8) (9) ). An abnormal lipid profile contributes to the development of CRC. Notarnicola et al (10) observed 84 patients with CRC and reported that the levels of total cholesterol (TC), low-density lipoprotein (LDL)-C and LDL-C/high-density lipoprotein-C were all increased in patients with metastasis compared with patients without metastasis. However, the mechanism of abnormal lipid metabolism in affecting CRC progress remains unclear.
Angiogenesis is an important contributing factor to tumor metastasis. CD34 is the major marker for tumor angiogenesis, invasiveness and metastasis. Tumor angiogenesis consists of numerous steps, during which vascular endothelial growth factor (VEGF) and angiotensin (ANG)2 are particularly important (11, 12) . VEGF promotes the growth and migration of vascular endothelial cells, induces tumor angiogenesis and promotes the permeability of microvessels and venules (13, 14) . ANG2 can facilitate angiogenesis by disrupting endothelial cell-pericyte interactions in primary tumors and enhancing the permeability of vessels (13) . ANG2 promotes the VEGF-induced migration and proliferation of ECs, and facilitates the growth of new blood vessels in the presence of growth factors (15) . Angiogenesis can be induced by chronic inflammation (16) , which may result from HFD (17) . Thus, HFD may contribute to the progress of CRC by promoting angiogenesis.
The aim of the present study was to observe the effect of HFD on the metastasis and angiogenesis of colon orthotopic transplantation tumors in BABL/c mice, and to identify the mechanism of the effect of HFD on metastasis. It was demonstrated that HFD increased the level of cytokines, and induced tumor angiogenesis, to promote colon orthotopic transplantation tumor metastasis in BALB/c mice.
Materials and methods

Materials.
ELISA kits for interleukin-6 (IL-6; cat. no. 550950), tumor necrosis factor (TNF)-α (cat. no. 560478) and mouse lipoprotein were purchased from BD Biosciences (Franklin Lakes, NJ, USA). Anti-vascular endothelial growth factor (VEGF) antibody (EP1176Y), anti-CD34 antibody (EP373Y) and anti-angiotensin 2 (ANG2) antibody [EPR2891 (2) ] (all from Abcam, Cambridge, UK; all rabbit monoclonal), and kits for the determination of triglyceride (TG; cat. no. 006304) and total cholesterol (TC; cat. no. 006301) were purchased from Beijing BHKT Clinical Reagent Co., Ltd. (Beijing, China).
Animals.
A total of 41 six-week-old BALB/c mice (specific pathogen-free grade; half male, half female; body weights ~20±2 g) were purchased from and housed at the Shanghai Laboratory Animals Center (SLAC) of the Chinese Academy of Sciences (Shanghai, China). The housing conditions were as follows: 24±2˚C, 50±10% relative humidity, and a 12-h light/dark cycle. The animals had ad libitum access to food and water. The housing facility and all animal experiments were conducted in accordance with the guidelines established by the Beijing Administration Office of Laboratory Animals; the study protocol was approved by the Institutional Animal Care and Use Committee of SLAC.
Cell line. CT26 mouse colon cancer cells were provided as a gift by SLAC. The cells were incubated at 37˚C. They were maintained in Dulbecco's modified Eagle's medium containing 100 ml/l fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 100,000 U/l of penicillin and 100 mg/l of streptomycin in a humidified atmosphere of 5% CO 2 .
Colon cancer orthograft model. CT26 cells (5x10 6 cells suspended in 0.2 ml Matrigel) were injected into the right axillary subcutaneous region of a BALB/c mouse. When the tumor grew to ~1 cm 3 , the mouse was sacrificed and the tumor was excised. The tumor lump was sliced into 1 mm 3 pieces to make a colon cancer orthograft model.
The remaining BALB/c mice were divided into the following four groups: Tumor, tumor-HFD, HFD and control, with 10 mice in each group. The mice in the tumor-HFD and HFD groups were fed with HFD as previously described (18) whereas the other two groups were fed with a control diet. The HFD contained 92 g/kg protein, 203 g/kg fat and 128 g/kg carbohydrate, while the control diet contained 78 g/kg protein, 22 g/kg fat and 320 g/kg carbohydrate.
At 4 weeks, the mice were fasted for 12 h prior to surgery. The mice were anesthetized by injection with 4.5% chloral hydrate into the abdominal cavity. Subsequent to disinfection, they were cut along the right midline to expose the colon, and the muscular layer of the colon was opened with 1 ml sterile needles. A piece of tumor was adhered to the cecum incision with medical OB biological glue in mice from the tumor-HFD and tumor groups, whereas mice in the HFD and control groups were treated with OB glue alone. The abdomen was closed. From the next day, the mice were fed with their previous diet continuously for 3 weeks.
Measurement of body and tumor weights. The body weights of mice were measured once a week with an electronic weighting scale. The tumor weights were measured by an electronic microbalance, following the sacrifice of mice and the excision of the tumors.
Quantification of metastasis.
Metastasis was scored at five levels: 1, no metastasis; 2, one incidence of visceral metastasis; 3, 2 incidences of visceral metastases; 4, 3 incidences of visceral metastases and 5, >4 incidences of visceral metastases.
Tissue preparation. All mice were sacrificed by the cervical dislocation method. Blood was sampled from the retro-orbital plexus. Blood serum was extracted by centrifugation (15,970 x g at 4˚C for 5 min) and stored at -20˚C until analysis. The lungs, liver, spleen, pancreas, greater omentum and distal rectum were stored in Eppendorf tubes with formalin at room temperature. Colon tumor tissues were stored at -80˚C.
Immunohistochemistry. Paraffin-embedded tissues were sectioned, deparaffinized, and rehydrated, and then washed in PBS (3x3 min). Antigen retrieval was performed in the microwave for 20 min in citrate buffer (2102-100; pH 6.0, 0.01 ml/l; BioVision, Inc., Milpitas, CA, USA); sections were left at room temperature to cool, washed in PBS 3 times for 3 min, treated with 0.3% H 2 O 2 at room temperature for endogenous peroxidase ablation (20 min) and washed in PBS 3 times for 3 min again. The sections were incubated with antibodies against CD34, VEGF and ANG2 (1:100) for 2 h at 37˚C. Subsequent to washing, the sections were incubated with goat anti-rabbit IgG, which was horseradish peroxidase-conjugated (1:300; A0208; Beyotime Institute of Biotechnology, Shanghai, China) at 37˚C for 30 min. Subsequent to further washing, the sections were reacted with 3,3-diaminobenzidine, left at room temperature without light for 10 min, and then counterstained with hematoxylin, dehydrated, cleared and mounted with neutral gums.
The positive proportion of immunohistochemical staining and the optical density (OD) were measured by an IMS Cell Image Analysis system (Shanghai ShenTeng Information Technology Co., Ltd., Shanghai, China). Each section was analyzed at least in three fields of view. The immunohistochemistry index was calculated as the positive proportion x OD.
Reverse transcription-polymerase chain reaction (RT-PCR).
Tumor tissues were treated with TRIzol (Thermo Fisher Scientific, Inc.), chloroform and isopropyl alcohol to extract RNA. Following the reverse transcription of RNA to cDNA (Moloney Murine Leukemia Virus; 200 U/ml; Invitrogen; Thermo Fisher Scientific, Inc.), primers were added for amplification with 40 cycles of 95˚C for 30 sec and 60˚C for 30 sec. The primers were synthesized by Shanghai Yingjun Biological Technology Co., Ltd. (Shanghai, China; Table I ). The Fluorescence quantitative PCR kit (Takara Biotechnology Co., Ltd., Dalian, China) was used according to the manufacturer's protocols. The products were subjected to a biological electrophoresis image analysis system for software-based PCR densitometry (FR-2000; Shanghai Furi Science & Technology Co., Ltd., Shanghai, China). GAPDH was used as a reference gene.
ELISA assays. Serum IL-6 (cat. no. 550950), TNF-α (cat. no. 560478), TG (cat. no. 006304), TC (cat. no. 006301) and lipoprotein a (cat. no. 006340) were examined by using Quantikine ELISA kits (BD Biosciences Company, USA) according to the manufacturer's protocol. Optical density was measured in an ELISA reader at 450 nm following a 15-min incubation at room temperature.
Data analysis. The measurement data are expressed as the mean ± standard deviation. Statistical analysis was performed using SPSS 21.0 (IBM Corp., Armonk, NY, USA). Comparisons between groups were tested by one-way analysis of variance followed by a least significant difference test. Differences in metastasis were analyzed by a Wilcoxon Rank-Sum test. Correlation analysis was performed by Pearson correlation coefficient. P<0.05 was considered to indicate a statistically significant difference.
Results
Normal mouse body weight, but not orthotopic tumor-transplanted mouse body weight, increases following HFD. The body weights of the mice were measured twice a week. There was no difference between the mean body weights of the four groups before the experiment (P>0.05). One week later, the body weights of mice in the HFD group had significantly increased compared with the control group (P<0.05), whereas the body weights of mice decreased following colon orthotopic transplantation in the tumor-HFD and tumor groups. At the end of the experiment, the mean weight of the mice was higher in the HFD group than in the tumor-HFD group or control group (P<0.05), and was lower in the tumor and tumor-HFD groups than in the control group (P<0.05). The body weights of the mice in the tumor-HFD group were the lowest among the four groups (Fig. 1) .
Metastasis severity is increased by HFD in mice transplanted
with orthotopic tumors. The mean tumor weight was detected when the mice were sacrificed at 3 weeks after the colon cancer orthotopic transplantation surgery. The tumor weight was greater in the tumor-HFD group (1.57±0.54 g) than in the tumor group (1.37±0.40 g), but there was no significant difference between these two groups (P=0.368; Fig. 2A) .
A total of 2 out of 10 mice died in the tumor-HFD group due to intestinal obstruction diagnosed by autopsy, while there was no mortality in the tumor group. The metastases in the lung, liver, spleen, pancreas, rectum and greater omentum were observed by immunohistochemistry. The metastases in the tumor group included two cases at level 1, five cases at level 2, two cases at level 3 and 1 case at level 4, whereas there were two cases at level 2, two cases at level 3, four cases at level 4 and 2 cases at level 5 in the tumor-HFD group. The severity of metastasis was greater in the tumor-HFD group than in the tumor group (P<0.05; Fig. 2B ).
Serum cholesterol level is increased in mice transplanted with orthotopic tumors following HFD.
ELISA was applied to determine whether HFD increased the serum cholesterol level. The serum cholesterol levels in the HFD and tumor-HFD groups were 5.10±0.84 and 5.51±1.93 mmol/l, respectively, which were higher than in the control group (3.29±0.48 mmol/l; P<0.05). No difference was observed in serum cholesterol levels between the tumor group (3.36±1.17 mmol/l) and the control group (P>0.05). No difference was observed in serum TG or lipoprotein levels among the four groups (P>0.05; Fig. 3 ).
Serum levels of IL-6 and TNF-α increase in mice transplanted with orthotopic tumors following HFD.
The results of ELISA revealed that the serum levels of IL-6 and TNF-α, two cytokines associated with inflammation, increased markedly (118.57±68.07 and 18.94±5.39 pg/ml, respectively) in the tumor-HFD group compared with the other groups (P<0.05; Fig. 4) . Although the serum levels of IL-6 and TNF-α in the tumor group (64.06±33.56, 10.69±6.74 pg/ml) were higher than those in the control group (29.79±14.78, 6.19±3.51 pg/ml), the differences were not statistically significant (P>0.05). The serum levels of IL-6 and TNF-α in the HFD group were similar to those in the control group (P>0.05).
Expression of CD34 protein, and VEGF and ANG2 protein and mRNA levels in colon cancer tissue, are increased following HFD.
The results of IHC staining for CD34, a glycoprotein expressed on endothelial cells and platelets, revealed that the expression of CD34 was higher in the tumor-HFD group than in the tumor group (Fig. 5A and B) . Similarly, the protein expression of VEGF, a key cytokine in tumor angiogenesis, was higher in the tumor-HFD group than in the tumor group (1.77±0.83 and 10.67±3.00); the differences were all statistically significant (P<0.05). The results of IHC staining for ANG2, another cytokine implicated in tumor angiogenesis, were 13.33±4.30 and 12.33±1.75 in the two groups, respectively, with no difference between them (P>0.05).
The results of RT-PCR demonstrated that the VEGF mRNA level was significantly higher in the tumor-HFD group than in the tumor group (1.24±0.69 vs. 0.74±0.23; P<0.05), whereas there the ANG2 mRNA level did not differ between the groups (Fig. 5C ).
Correlation analysis between IL-6, TNF-α, CD34 and VEGF, and metastasis.
Correlation analysis results demonstrated that the frequency of metastasis was associated with the IL-6 serum level (r=0.61), and the expression of CD34 (r=0.941) and VEGF (0.679) protein in tumor tissue (all P<0.05). There was no evident correlation between metastasis and TNF-α (P>0.05). 
Discussion
The purpose of the present study was to determine whether HFD increases colon tumor metastasis in BALB/c mice. It was observed that the metastasis frequency was more severe, with a higher level of serum cholesterol, in the tumor-HFD group compared with the tumor group. This indicated that high cholesterol induced by HFD may have served an important role in the metastasis of colon cancer. The link between dysregulated lipid levels, including high levels of cholesterol, LDL-C and TG, and colon cancer progression has previously been reported (19) . Another previous study indicated that a high serum cholesterol level was associated with the distant metastasis of colon cancer (10) . Cholesterol is a crucial component of cell membranes, and contributes to the organization of lipid rafts, which contain a large number of cancer-associated signaling and adhesion molecules (20) . Due to the increase in the cholesterol level of tumor cells, increased lipid synthesis is also recognized as a common feature of metabolic reprogramming in cancer cells (21) . Dysregulated cholesterol synthesis and sterol-dependent proliferation have been identified in various cancer cell types and may lead to cancer progression (21) .
In the present study, it was observed that HFD increased the serum IL-6 and TNF-α levels of mice with colon cancer. Previous studies have indicated that the metabolic syndrome induced by HFD can cause inflammation (22) , particularly through the oxidation of cholesterol (23, 24) . However, HFD did not induce an inflammatory effect in normal mice, which may be due to the limited time that HFD was received. In the colon cancer model mice fed a normal diet, IL-6 and TNF-α increased to a non-significant extent compared with the control mice. A correlation analysis identified that metastasis may have been associated with the serum level of IL-6. This indicated that the inflammation induced by HFD may contribute to colon cancer metastasis.
Clinical and epidemiological research has demonstrated an association between cancer and inflammatory metabolic diseases; common molecular characteristics between the two have been demonstrated. Hirsch et al (21) hypothesized that there was a common core signaling pathway network controlling normal cell growth and behavior. Once the core gene network is affected by genetics or the environment, a range of diseases develop, which may account for the association between cancer and metabolic disease. Regarding how a common transcriptional program contributed to this diverse range of human diseases, Hirsch et al suggested that the interplay between cell-type-specific factors and a common transcriptional program leads to cell-type-specific transcription profiles and phenotypes associated with these specific disease states. In this view, the combination of cell-type-specific factors with a common disease program can lead to inappropriate cell proliferation as associated with either cancer or metabolic diseases (21) . Inflammation serves an important role in both colon cancer and metabolic diseases (25, 26) , which may be the main mechanism for the dysregulation of cholesterol, as induced by HFD, promoting colon cancer metastasis.
In the tumor microenvironment, inflammatory factors affect tumor angiogenesis (27) . In the present study, HFD increased the CD34 in tumor tissue, in addition to the serum levels of IL-6 and TNF-α in colon cancer model mice. IL-6 and TNF-α have been demonstrated to serve important roles in tumor angiogenesis (28, 29) . VEGF is the most critical cytokine in angiogenesis; Eldesoky et al (30) reported that the serum levels of IL-6 and VEGF from 35 patients with colon cancer prior to surgery were higher than in a control group, and the patients that experienced higher cancer invasiveness and metastasis had higher IL-6 and VEGF levels. TNF-α derived from the tumor can promote angiogenesis by promoting the secretion of VEGF by fibroblasts (31) . Likewise, tumors derived from cells with TNF-α knockdown exhibit a phenotype with reduced vascularization and invasiveness (32) .
The increased CD34 and VEGF protein and mRNA in tumor tissue indicated that tumor angiogenesis likely increased in colon cancer model mice that received HFD. As ANG2 protein and mRNA were not elevated in tumor tissues by HFD, VEGF induced by HFD may have promoted tumor angiogenesis. A correlation analysis demonstrated that metastasis was associated with the expression of CD34 and VEGF protein in tumor tissue. This indicated that the metastasis promotion by HFD may be associated with the induced inflammatory effect and angiogenesis. However, the specific mechanism remains to be determined through further study.
In conclusion, HFD promoted the distant metastasis of colon cancer model mice. HFD also elevated the serum level of cholesterol and the pro-inflammatory cytokines IL-6 and TNF-α, and potentially promoted angiogenesis in colon cancer model mice.
